Literature DB >> 15836594

Calcineurin inhibitor-induced headache: clinical characteristics and possible mechanisms.

Uta Ferrari1, Monika Empl, Kwang Sik Kim, Petra Sostak, Stefanie Förderreuther, Andreas Straube.   

Abstract

OBJECTIVE: To classify the headache syndromes under treatment with calcineurin inhibitors and to investigate whether the latter influence the nitric oxide production of human brain microvascular cells (HBMEC).
BACKGROUND: Single cases of cyclosporine-induced headaches have been reported. Since calcineurin inhibitors are known to influence the renal metabolism of NO, a key molecule in tension-type headache and migraine, we were interested whether calcineurin inhibitors might change NO metabolism in HBMEC as well. DESIGN AND METHODS: Headache symptoms of 74 patients receiving cyclosporine and/or tacrolimus for organ transplantation were retrospectively assessed. Furthermore, the effect of cyclosporine and tacrolimus on nitric oxide production in human brain microvascular endothelial cells was investigated after incubation.
RESULTS: Only 18 of the 74 patients reported no headache 1-36 months after liver, lung, or bone-marrow transplantation, 28 reported a new headache, and 17 an increase in the frequency or intensity of a pre-existing headache. The headache was generally classified as migraine without aura (IHS 1.1) or migraine-like headache (IHS 1.6). Furthermore, we found significantly increased NO production after co-incubation of calcineurin inhibitors with human brain microvascular endothelial cells.
CONCLUSION: The pathophysiological mechanism of these headaches may be connected with an endothelial dysfunction in terms of increased production of NO.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15836594     DOI: 10.1111/j.1526-4610.2005.05046.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  11 in total

1.  Spontaneous intracranial hypotension-hypovolemia associated with tacrolimus.

Authors:  Andrew H Ahn; Brian D Berman; William P Dillon
Journal:  Headache       Date:  2010-05-31       Impact factor: 5.887

2.  A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura.

Authors:  Ronald G Lafrenière; M Zameel Cader; Jean-François Poulin; Isabelle Andres-Enguix; Maryse Simoneau; Namrata Gupta; Karine Boisvert; François Lafrenière; Shannon McLaughlan; Marie-Pierre Dubé; Martin M Marcinkiewicz; Sreeram Ramagopalan; Olaf Ansorge; Bernard Brais; Jorge Sequeiros; Jose Maria Pereira-Monteiro; Lyn R Griffiths; Stephen J Tucker; George Ebers; Guy A Rouleau
Journal:  Nat Med       Date:  2010-09-26       Impact factor: 53.440

3.  Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance.

Authors:  D Mathews; John Mathews; N P Jones
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

4.  [Primary headaches and the influence of inflammatory diseases of the CNS and their respective immunmodulatory therapy].

Authors:  M Empl; A Straube
Journal:  Schmerz       Date:  2007-10       Impact factor: 1.107

5.  Familial hemiplegic migraine Ca(v)2.1 channel mutation R192Q enhances ATP-gated P2X3 receptor activity of mouse sensory ganglion neurons mediating trigeminal pain.

Authors:  Asha Nair; Manuela Simonetti; Nicol Birsa; Michel D Ferrari; Arn M J M van den Maagdenberg; Rashid Giniatullin; Andrea Nistri; Elsa Fabbretti
Journal:  Mol Pain       Date:  2010-08-24       Impact factor: 3.395

Review 6.  Focus on headache as an adverse reaction to drugs.

Authors:  Anna Ferrari; Luca Spaccapelo; Daniela Gallesi; Emilio Sternieri
Journal:  J Headache Pain       Date:  2009-06-04       Impact factor: 7.277

Review 7.  Two-Pore Domain Potassium Channel in Neurological Disorders.

Authors:  Punita Aggarwal; Sanjiv Singh; V Ravichandiran
Journal:  J Membr Biol       Date:  2021-06-24       Impact factor: 1.843

8.  A Role for K2P Channels in the Operation of Somatosensory Nociceptors.

Authors:  Leigh D Plant
Journal:  Front Mol Neurosci       Date:  2012-03-05       Impact factor: 5.639

9.  Methotrexate and cyclosporine treatments modify the activities of dipeptidyl peptidase IV and prolyl oligopeptidase in murine macrophages.

Authors:  R A Olivo; N G Nascimento; C F P Teixeira; P F Silveira
Journal:  Clin Dev Immunol       Date:  2008

10.  Brain natriuretic peptide constitutively downregulates P2X3 receptors by controlling their phosphorylation state and membrane localization.

Authors:  Anna Marchenkova; Sandra Vilotti; Elsa Fabbretti; Andrea Nistri
Journal:  Mol Pain       Date:  2015-11-14       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.